tbuckley/cabot-search huggingface dataset:
Functions of Glycosylation Cooled Rabbit Platelets In Vivo and In Vitro.
Authors: Bao-An Chen, Cheng-Yin Huang, Xiao-Ping Pei, Chong Gao, Jia-Hua Ding, Yun-Yu Sun, Jun Wang, Jiang Cheng, Guang-Yao Shi, Ning-Na Chen, Fei Fei
Journal: Blood (2006)
Clinical significance of obesity index (VFA versus BMI) as a risk factor for gastric cancer surgery.
Authors: Kyo Young Song, Jung Ho Shim
Journal: Journal of Clinical Oncology (2012)

139 Background: Obesity is considered as a major perioperative risk factor in various cancer surgeries. We aimed to elucidate the effect of two different obesity index, such as VFA (visceral fat area) and BMI (body mass index), on gastrectomy. Methods: From Mar 2009 to July 2010, 632 patients with diagnosed gastric carcinoma underwent curative gastrecomy at Seoul St. Mary’s hospital. We reviewed patients’ clinicopatholic data and collected 187 patients who had data including BMI, VFA and SFA. Patients with body mass index (BMI) ≥ 25 kg/m 2 were defined as obese and visceral fat area (VFA) ≥ 100 were defined as centrally obese. Results: Out of a total 187 patients, eighty patients were in the high BMI group and 107 patients were in the low BMI group. We selected patients with high VFA and low BMI (group A) and compared to the patients with low VFA and low BMI (group B). Out of a total 107 patients in low BMI, seventy three patients were censored as high VFA, and age older than 60 and male patients were prevalent in this group (p=0.045 and 0.046). The operation time (OT) and estimated blood loss (EBL) were significantly higher in group A than group B (p=0.043 and p=0.05). Conclusions: VFA and BMI are correlated each other and successfully represent patients’ obesity. However in selected patients, such as male patients with age older than sixty, VFA more practically represent their obesity.
Biliary stent complications in clinical trials for advanced pancreatic cancer.
Authors: A. M. Espinoza, A. H. Ko, J. W. Ostroff, A. P. Venook, E. K. Bergsland, R. K. Kelley, E. Dito, A. Ong, M. A. Tempero
Journal: Journal of Clinical Oncology (2011)

e14665 Background: Most patients (pts) with pancreatic cancer are unresectable at diagnosis. About 70% of these pts will develop obstructive jaundice requiring intervention. Most commonly, relief of obstruction is performed endoscopically, with placement of either a plastic stent (PS) or metal stent (MS). NCCN guidelines recommend metal stents because of a lower occlusion rate. We did a retrospective analysis of biliary stent outcomes in pts with advanced pancreatic cancer (APC) who were treated on a series of phase II trials at UCSF. Methods: We reviewed charts of pts with previously untreated APC who were enrolled on 3 sequential trials that investigated gemcitabine-based combination chemotherapy regimens. Primary objective: to determine biliary stent outcomes including stent complication rate, rate of treatment (tx) delays due to stent complications, and total # of endoscopic interventions per pt. Outcomes were compared for pts with PS vs MS. Results: 134 pts with APC were identified. Median age = 59, and all pts were ECOG PS 0-1. 59 pts (44%) had primary lesions in the pancreatic head/uncinate. 20 pts (15%) had palliative bypass surgery at diagnosis. Of the remaining pts, 22 (19%) required intervention for biliary obstruction prior to the start of tx. Nine pts had MS, 13 had PS in place at the start of tx. Pts with PS were put on a regular schedule of stent exchanges. Seven pts (54%) in the PS group had stent complications during tx; in the MS group 2 pts (22%) had complications. These episodes led to tx delays in 4 pts (31%) in the PS group. There were no tx delays attributable to stent complications in the MS group. The average # of endoscopic or percutaneous procedures performed after the start of tx was 2.85 in the PS group and 1 in the MS group. Of pts who started tx with a PS, 62% ultimately had a MS placed. Conclusions: In our population of clinical trial APC pts, there was a higher rate of complications in pts with PS despite scheduled stent exchanges. This data supports placement of metal stents, especially if pts will be treated with more myelosuppressive combination chemotherapy regimens.
Methodologic challenges in assessing patient-reported outcomes among women with relapsed/refractory ovarian cancer.
Authors: X. Xu, M. Markman
Journal: Journal of Clinical Oncology (2010)

e15551 Background: Currently there are no curative therapies available for ovarian cancer. Treatments for relapsed/refractory (R/R) ovarian cancer aim to maintain quality of life (QOL) and control symptoms. The objective of this study was to examine how chemotherapy (chemo) impacts patient-reported outcomes (PRO) in women with R/R ovarian cancer, and to identify methodological issues affecting PRO assessments. Methods: A literature review was performed to identify studies in which PRO was assessed in women with R/R ovarian cancer. Publications meeting the following search criteria were analyzed: English language; original clinical studies published between 01/1998 and 05/2009; focus on treatment of R/R ovarian cancer; PRO/QOL reported. Results: Twenty-nine studies were reviewed (8 phase III, 16 phase II, and 5 unspecified studies); 12 PRO instruments were identified. The EORTC QLQ-C30 was the most frequently used overall (14/29) and in phase III studies (6/8), followed by the FACT-O (9/29). PRO were assessed at baseline in all studies and during various times that coincided with chemo cycles and during treatment follow-up. Significant changes in PRO over time were observed in half of the studies and most often for symptom control, with few significant changes observed for other identifiers of well-being; none of the significant changes was interpreted using the minimally important differences parameter. PRO completion rates dropped substantially over time, limiting samples available for assessment and clouding interpretation of results. The impact of sample size, missing data, and time points of assessment on PRO change over time finding were not suitably addressed in the studies. Further, there are inconsistent PRO findings from studies with same chemo regimens even when using the same instruments, with methodological issues accounting for some discrepancies. Conclusions: PRO among women with R/R ovarian cancer is limited in quality. More data are needed from R/R ovarian cancer studies to identify not only the most appropriate PRO instruments, but also methodologic strategies necessary to yield useful PRO data. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration MedImmune MedImmune MedImmune MedImmune
Expansion of a lymphocyte subset expressing a spliced FKBP51 isoform in melanoma patients.
Authors: Maria Fiammetta Romano, Anna D'Angelillo, Paolo Antonio Ascierto, Ester Simeone, Stefania Staibano, Paolo D'Arrigo, Michele Russo, Rita Bisogni, Simona Romano
Journal: Journal of Clinical Oncology (2015)

e20070 Background: We identified a spliced isoform of FKBP51 (FKBP51s) as a factor associated to PDL-1. FKBP51s stains TILs and is measurable in PBMC of melanoma patients. We also provided evidence that FKBP51s is a tumor edited and tolerance associated signature. Methods: qPCR served to measure FKBP51s in RNA extracted from PBMC of 102 melanoma patients (stages III, IV) undergoing immunotherapy (IT) with ipilimumab and 125 age matched healthy donors. Flow cytometry served to analyze protein expression in PBMC subsets of 61 patients and 56 controls. Fourty patients were analyzed also at the end of IT. Results: Compared with control value, FKBP51s transcript increased in patients (p < 0.01). In non responders, such transcript further increased after IT (p = 0.02). CD8 lymphocytes resulted increased in patients (32%+10) vs controls (27%+10) (p < 0.01). CD8 double staining with FKBP51s revealed that 20%+8 and 13%+7 were CD8+FKBP51s+, in patients and controls respectively (p < 0.01). The ratio CD8tot/CD8+FKBP51s+ was 1.9+0.7 and 2.7+1.4 for patients and controls (p < 0.01). In responders, IT produced a decrease of CD8+FKBP51s+ subset to 11%+6 (p = 0.01). Accordingly, in responders, the ratio CD8tot/CD8+FKBP51s+ increased to 2.8+1.0 (p = 0.03). In non responders, no variation of CD8+FKBP51s+ count or CD8tot/CD8+FKBP51s+ ratio was registered. Total CD4 lymphocytes did not differ between patients and controls, even if the FKBP51s+ component resulted increased and FKBP51s- decreased. No significant variation of such subsets was registered before and after IT. Interestingly, FKBP51s stained 55%+25 and 36%+27 of CD25 lymphocytes, in patients and controls respectively (p < 0.01). In responders, FKBP51s stained 68%+22 and 41%+16 of CD25 lymphocytes, before and after IT respectively (p < 0.01). In non responders, FKBP51s expression in CD25 lymphocytes was 53%+26 and remained unchanged after IT. Conclusions: FKBP51s transcript level may provide a guidance for assessing IT response. CD8+/FKBP51s+ subset is very sensitive to IT efficacy and the ratio CD8tot/CD8 FKBP51s+ is a promising tool to monitor IT. FKBP51s might also be a marker of a Treg subset which decreases in response to IT. Ongoing studies will address this issue.
Antigen Presentation Profiling Reveals T-Cell Recognition of Lymphoma Immunoglobulin Neoantigens
Authors: Michael Khodadoust, Niclas Olsson, Lisa Wagar, Binbin Chen, Keith Rawson, Chih Long Liu, David Steiner, Samhita Rao, Lichao Zhang, Henning Stehr, Aaron M Newman, Debra K Czerwinski, Victoria Carlton, Martin Moorhead, Malek Faham, Holbrook Kohrt, Michael R Green, Mark M Davis, Ron Levy, Joshua Elias, Ash A. Alizadeh
Journal: Blood (2016)
The role of PET probe–guided open biopsy in managing patients with lymphoma.
Authors: S. Misra, K. Cherian, P. J. Dipasco, I. S. Lossos, E. Avisar
Journal: Journal of Clinical Oncology (2011)

e18547 Background: The aim of this study was to determine the correlation between results acquired via both (18)F-flourodeoxyglucose positron emission tomography (FDG PET) probe guided open biopsy and core biopsy, and to assess the validity of core biopsy as the current standard of care when deriving a diagnosis of lymphoma. Methods: We performed a retrospective chart review of 10 patients who had failed core biopsies. All the patients had previous disease, and were being evaluated for recurrent disease because of new FDG avid lymph nodes. Our patient group included six males and four females, ranging from 19 to 76 years of age. The manner of core biopsy employed varied with six patients getting computed tomography guidance, one patient by ultrasound, one patient by esophagogastroduodenoscopy, one by thoracoscopy, and one bone marrow biopsy. Results: On the preliminary core biopsy, CT guided biopsy was indeterminate for 3 out of 6 patients, negative for 2 out of 6 patients, and unable to differentiate the subtype and growth pattern for 1 patient. The US-guided, EGD, and bone marrow biopsies for the remaining 4 patients were all negative. In four separate instances, patients had a negative biopsy even on repeat attempt, two cores and two non PET probe-guided open biopsies. PET probe-guided open biopsy correctly diagnosed all these patients, including the specific subtype and growth pattern. The most common diagnosis was malignant non-Hodgkin’s lymphoma (6/10), followed by Hodgkin’s lymphoma (4/10). Conclusions: Our series suggests that FDG PET probe guided open biopsy is instrumental in diagnosis and classification of recurrent lymphoma. Similar findings might also apply to the initial diagnosis of lymphoma. Core biopsy alone, even when guided by other imaging tools, is often insufficient for a correct diagnosis.
Id/KLH Vaccine (FavId™) Following Treatment with Rituximab: An Analysis of Response Rate Improvement (RRI) and Time-to-Progression (TTP) in Follicular Lymphoma (FL).
Authors: Omer N. Koc, Charles Redfern, Peter H. Wiernik, Fred Rosenfelt, Jane N. Winter, Troy H. Guthrie, Lawrence Kaplan, Peter Holman, John Densmore, John Hainsworth, Thomas Lin, Rene A. Castillo, Nalini Janakiraman, John F. Bender
Journal: Blood (2004)
The final report of post-marketing surveillance for cetuximab in colorectal cancer in Japan.
Authors: K. Yamaguchi, T. Satoh, T. Watanabe, M. Ishiguro, K. Maruyama, T. Seriu, T. Miki, H. Ito, K. Sugihara, Y. Sakata
Journal: Journal of Clinical Oncology (2011)

590 Background: Cetuximab (ERBITUX) was approved in Jul 2008 in Japan with indication for EGFR-positive and unresectable metastatic or refractory colorectal cancer. Post-marketing surveillance is required by Japanese Health Authority to collect, obtain, verify or validate information on the safety, efficacy and quality of medicines. We conducted this surveillance in all patients treated with cetuximab to access in practical use since clinical data on Japanese patients are limited. Methods: The target number of patients was 1,800. Following adverse drug reactions were investigated: infusion reaction, skin disorders, interstitial lung diseases, electrolyte abnormalities (including hypomagnesemia), heart toxicities, gastrointestinal disorders, thrombosis/embolism, delayed wound healing, and eye disorders. Results: Between Sep 2008 until Jan 2010, 2,126 pts registered, 2,006 pts were evaluable for safety (safety population), 1,687 pts for efficacy (efficacy population). Of the 2,006 pts, 1,975 pts (98.5%) were EGFR-positive. Patients characteristics: male/female; 1,234/772 (61.5%/38.5%), median age; 64 (range 18-87), site of primary tumor; colon/rectal/others (multiple selection); 1,235/775/3 (61.6%/38.6%/0.2%), PS0/PS1; 1,370/630 (68.3%/31.4%), combination chemotherapy; cetuximab monotherapy/CPT-11/FOLFIRI: 460/1,255/256 (22.9%/62.56%/12.8%). Of the 2,006 pts, 133 pts (6.6%) and 1,869 pts (93.2%) were treated in second-line and in third-line or later treatment, respectively. The adverse drug reactions incidence was 89.9%. Incidence of skin disorders, gastrointestinal disorders, electrolyte abnormality including hypomagnesaemia, and infusion reaction were 83.7%, 23.1%, 11.5%, and 5.7%, respectively. Efficacy result: Of the 1,687 pts, 658 pts (39.0%) were evaluated to be effective. Of the 658 pts, 614 pts (93.3%) experienced skin adverse reactions. Conclusions: This post-marketing surveillance confirms the safety and efficacy of cetuximab in the Japanese population treated in clinical practice. The outcome of this surveillance with Japanese 2,006 pts would be useful for clinical use of cetuximab. [Table: see text]
Use of cetuximab in a real-life setting in France with respect to KRAS status: Preliminary results of EREBUS cohort study.
Authors: D. Smith, M. Rouyer, E. Francois, E. Mitry, A. Monnereau, A. Sa Cunha, E. Bignon, A. Le Monies, N. Moore, A. Fourrier-Réglat
Journal: Journal of Clinical Oncology (2011)

e14094 Background: Cetuximab demonstrated survival outcome improvement in metastatic colorectal cancer (mCRC). Cetuximab was first launched as a second-line therapy in mCRC. In July 2008, this indication was extended to first-line therapy and restricted to mCRC patients with wild-type (wt) KRAS gene. We present here the preliminary results of the French EREBUS cohort study to describe cetuximab prescription patterns according to KRAS status in a real-life setting. Methods: EREBUS is a cohort study conducted in 93 French centres. Patients initiating cetuximab between Jan and Dec 2009 were identified from nominative hospital pharmacy dispensations. The cohort included mCRC patients treated in first-line were followed for 12 months to evaluate the rate of metastases resection, usage patterns, safety and effectiveness of cetuximab. Results: To date, 1044 patients treated by cetuximab for colorectal cancer have been identified. The investigation of KRAS status was performed in 94.3% patients, and of these 94.7% had wt KRAS gene. The investigation was performed on primary tumour (83.0%), on metastases (16.0%) or both (1.0%). The main reasons of absence of KRAS status investigation were: previous treatment by cetuximab (63.4%) and absence of available tumour material or technical issue with analysis (26.8%). Investigation of EGFR expression was performed for only 2.4% patients. Cetuximab was mainly prescribed in mCRC (97.9%): 34.5% as first-line therapy, 34.1% as second-line, 21.4% as third-line and 9.6% as fourth-line or more. Investigation of KRAS and wt status were similar whatever the type of treatment (investigation: between 93.2% and 100.0%; wt status: between 93.6% and 100.0%). Among the 74 mCRC patients treated in first-line: cetuximab was combined with irinotecan-based regimen (61.6%), oxaliplatin-based regimen (37.0%) or FOLFIRINOX (1.4%). Cetuximab was given weekly (31.1%) or every 2 weeks (68.9%). Conclusions: EREBUS is the first post-marketing cohort study conducted in France to describe the usage patterns of cetuximab. Extensive investigation of KRAS status and the high proportion of patients with wt status indicates adherence to market authorisation, although EGFR expression remains rarely investigated.
Cause-specific mortality in a large cohort of prostate cancer patients treated with brachytherapy
Authors: B. J. Moran, M. H. Braccioforte
Journal: Journal of Clinical Oncology (2008)

5154 Background: The purpose of this study was to evaluate causes of death in a large cohort of prostate cancer patients treated with interstitial permanent prostate brachytherapy. Methods: 8,215 patients underwent prostate brachytherapy at a single institution between October 1997 and October 2007. Mean patient age was 68.9 ± 7.6 years. 48.2% of patients were considered low risk, 39% were intermediate risk and 11.8% were high risk as classified by the D’Amico risk groups. Overall, 2,522 patients (30.7%) received androgen deprivation therapy. Median follow-up time was 4.6 years. Specific cause of death was evaluated as well as multiple variables including risk group, smoking status, presence or absence of diabetes, hypercholesterolemia and hypertension. Results: Kaplan-Meier survival analysis demonstrated prostate cancer specific survival was 97.3% (99.8%, 98.0% and 94.1% for Low, Intermediate and High risk patients, respectively). The overall survival for the patient population was 76.9% (83.2%, 80.5% and 67.0% for Low, Intermediate and High risk patients, respectively). 90% of deceased patients were ≥ 65 years old. 43% of all deaths were from cancer, however, only 32% of the cancer deaths were due to prostate cancer. Cardiovascular deaths accounted for 25% of all deaths, with myocardial infarction as the leading event. Table 1 provides additional information on the deceased patient cohort. Conclusions: Patients undergoing interstitial permanent prostate brachytherapy have excellent cause-specific and overall survival rates. As techniques in early detection and treatment evolve, these rates will continue to improve. This data is valuable for future patient consultation regarding prostate cancer treatment options and prognosis. Analysis of Deceased Patients Cause of Death All Causes Prostate Cancer Cardiovascular Mean Time to Death (months) 44.9 48.6 40.5 Mean Age (years) 72.7 73.2 72.4 Received Androgen Deprivation Therapy (%) 40.9 50.9 43.1 Risk Group (%): Low, Intermediate 35.5, 42.2 12.7, 34.5 34.3, 44.1 Risk Group (%): High, Salvage 18.4, 4.0 38.2, 14.5 19.6, 2.0 Smoking Status (%) Current, Previous, Never 18.1, 48.7, 33.2 21.8, 50.9, 27.3 14.7, 55.9, 29.4 Diabetes (%) Present 16.3 9.1 19.6 Hypercholesterolemia (%) Present 20.6 20.0 23.5 Hypertension (%) Present 51.3 40.0 59.8 Note: Salvage patients excluded from Kaplan-Meier analysis No significant financial relationships to disclose.
Epidemiology and outcome of sarcomatoid renal cell cancer compared to clear cell renal cancer: A Surveillance, Epidemiology, and End Results (SEER) database review.
Authors: Mohammed Nawaf Kanaan, Parminder Singh, Frederick R. Ahmann, Amit Balkrishna Agarwal
Journal: Journal of Clinical Oncology (2014)

504 Background: Sarcomatoid renal cell carcinoma (SRCCa) is a rare type of RCCa. Few case series in literature indicated its dismal prognosis. We studied the epidemiology and survival outcome of SRCCa compared to clear RCCa (CRCCa) by reviewing the SEER database. Methods: SEER database (8.1.2) was reviewed for patients (pts) with histologically confirmed SRCCa and CRCCa between 2004 -2007. Variables included were: age, race, gender, laterality, surgery of primary RCCa and AJCC stage. Primary outcome was 3 year Disease Specific Survival (DSS). Data was analyzed using Chi square, Kaplan Meier and Cox proportional hazard model. Results: A total of 7,653 pts with CRCCa and 540 with SRCCa were included between 2004 and 2007. Mean age in SRCCa was 61 compared to 62 yrs in CRCCa. White to black race ratio was 7.5:1 in both types. Left primary was 54% in SRCCa and 51% in CRCCa. Male to female ratio was 1.9:1 in SRCCa and 1.7:1 in CRCCa (Table). The main stage at presentation was stage IV (63%) in SRCCa and stage I (53%) in CRCCa. Surgery rate was higher in SRCCa in stage II and IV, same between two groups in stage II and higher in CRCCa in stage I. When we analyzed the effect of RCCa type on DSS for each stage separately, SRCCa had worse 3-year DSS in stage I, II, III and IV independent of age, sex, race, gender and surgery. The Hazard Ratio was 4.97 for stage I, 11.37 for stage II, 3.91 for stage III and 1.58 for stage IV (p &lt;0.001). Conclusions: SRCCa have no statistical significant difference in age, race, gender and laterality compared to CRCCa. When compared stage to stage, SRCCa have worse outcome than RCCa even after adjusting for potential confounders including age, race, gender and surgery. The effect appears to be less prominent in higher stages than in lower stages of the disease. [Table: see text]
Improved outcome of childhood AML with intensive therapy and optimized supportive care: Experience of King Abdulaziz Medical City, National Guard Hospital, Jeddah, Saudi Arabia.
Authors: T. M. Khattab, W. A. Jastaniah, S. K. Felimban
Journal: Journal of Clinical Oncology (2010)

e20003 Background: Outcome of childhood acute myeloid leukemia (AML) has improved during past 3 decades. This is a result of treatment intensification and improved supportive care. Supportive care has improved in our center with improvement of infection management and control (HEPA filter fixed on March 2003). Objectives: To review outcome and treatment related mortality (TRM) of childhood AML in our center over the past 3 decades and analyze outcome based on treatment eras. Methods: We reviewed patients files from 1986-1996 (1st era) where BFM-based therapy was used and from 1996-2009; MRC-based therapy was used. This change in therapy resulted in intensification of cytarabine and adriamycin dose by 3.5 and 2 times that of the BFM; respectively. The MRC-based therapy period was subdivided into 2 eras; 1996-2003 (2nd era) and 2003-2009 (3rd era), before and after fixation of HEPA filter. We analyzed the effect of treatment intensification and improved supportive care on TRM, Disease Related Mortality (DRM) and Overall Survival (OS). Results: Seventy four consecutive patients were analyzed. The mean age was 6 years (range 0.7 – 14), Male: Female ratio (3.4:4). Twenty two patients received BFM-based therapy and 52 received MRC-based therapy. Analyzing the effect of treatment intensification showed improvement in DRM and OS from 54% to 33% and from 9% to 58%; respectively. Twenty out of 52 patients received MRC- based therapy before HEPA filter instillation (2nd era) and 32/52 after HEPA filter instillation (3rd era). TRM declined from 36% to 20% then to 3%; respectively. However when comparing DRM between the 2nd and 3rd era we noted an increase in DRM from 20% to 41% despite a decline in TRM. Conclusions: Childhood AML remains a challenging disease, however treatment intensification and improvement in supportive care had a major impact on treatment outcome in our center. Optimizing supportive care may allow further intensification of therapy in AML to further improve outcome in our population. No significant financial relationships to disclose.